Published in J Clin Microbiol on April 01, 1992
Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii. J Clin Microbiol (1993) 0.92
Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia. Antimicrob Agents Chemother (1997) 0.82
Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci. J Clin Microbiol (1994) 0.81
Cefixime disk susceptibility test criteria. J Clin Microbiol (1986) 1.79
Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests. J Clin Microbiol (1987) 1.71
In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin. Diagn Microbiol Infect Dis (1992) 1.23
Disk diffusion susceptibility testing for LY163892 (KT-3777), a new orally administered 1-carbacephem. J Clin Microbiol (1988) 1.08
In vitro antibacterial activity of FK482, a new orally active cephalosporin. J Antibiot (Tokyo) (1988) 1.02
Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. J Antibiot (Tokyo) (1988) 0.99
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother (1996) 3.16
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. Diagn Microbiol Infect Dis (1995) 2.87
Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol (1996) 2.53
In vitro activity of CP-74667 compared with four other fluoroquinolones. Diagn Microbiol Infect Dis (1992) 2.00
Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. Diagn Microbiol Infect Dis (1997) 1.95
Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group. Diagn Microbiol Infect Dis (1994) 1.69
E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates. J Clin Microbiol (1993) 1.62
Critical appraisal of E test for the detection of fluoroquinolone resistance. J Antimicrob Chemother (1996) 1.60
Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group. Diagn Microbiol Infect Dis (1998) 1.47
Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates. Diagn Microbiol Infect Dis (1994) 1.37
Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628. Diagn Microbiol Infect Dis (1992) 1.31
In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob Agents Chemother (1997) 1.27
In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin. Diagn Microbiol Infect Dis (1992) 1.23
In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. Eur J Clin Microbiol Infect Dis (1992) 1.16
In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates. J Antimicrob Chemother (1993) 1.13
Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan. J Clin Microbiol (1991) 1.11
Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines. Diagn Microbiol Infect Dis (1999) 1.10
Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study Group. Diagn Microbiol Infect Dis (1999) 1.08
The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis (1998) 1.07
Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study Group. Diagn Microbiol Infect Dis (1999) 1.04
Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines. Diagn Microbiol Infect Dis (1992) 0.97
Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study. Diagn Microbiol Infect Dis (1994) 0.96
Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group. J Clin Microbiol (1999) 0.96
Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States. Antimicrob Agents Chemother (1991) 0.95
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin. J Clin Microbiol (1992) 0.94
Emerging multiply resistant enterococci among clinical isolates. II. Validation of the etest to recognize glycopeptide-resistant strains. Diagn Microbiol Infect Dis (1995) 0.94
Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species. Eur J Clin Microbiol Infect Dis (1992) 0.93
Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii. J Clin Microbiol (1993) 0.92
Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae. J Clin Microbiol (1999) 0.92
In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species. Eur J Clin Microbiol Infect Dis (1990) 0.91
Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks. Diagn Microbiol Infect Dis (1992) 0.90
Evaluation of the Etest for antimicrobial spectrum and potency determinations of anaerobes associated with bacterial vaginosis and peritonitis. Diagn Microbiol Infect Dis (1994) 0.89
In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis (1994) 0.89
Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods. Diagn Microbiol Infect Dis (1994) 0.89
Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards. Diagn Microbiol Infect Dis (1994) 0.88
Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines. Diagn Microbiol Infect Dis (1992) 0.87
Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1. J Clin Microbiol (1995) 0.86
Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals. Diagn Microbiol Infect Dis (1994) 0.86
Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group. Diagn Microbiol Infect Dis (1999) 0.85
Quality control guidelines for Haemophilus test medium MIC susceptibility tests with cefmetazole, cefpodoxime, CI-960 (PD127391, AM-1090), and RU29246. J Antimicrob Chemother (1991) 0.85
Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin. J Clin Microbiol (1992) 0.85
Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates. Antimicrob Agents Chemother (1992) 0.85
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum. Diagn Microbiol Infect Dis (1992) 0.84
Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results. Diagn Microbiol Infect Dis (1994) 0.84
Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group. Diagn Microbiol Infect Dis (1999) 0.83
Quality control guidelines for disk diffusion and broth microdilution antimicrobial susceptibility tests with seven drugs for veterinary applications. J Clin Microbiol (2000) 0.83
False resistance results using 5 micrograms cefixime disks to test Haemophilus influenzae. Eur J Clin Microbiol Infect Dis (1991) 0.82
Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria. Diagn Microbiol Infect Dis (1993) 0.81
In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds. Eur J Clin Microbiol Infect Dis (1993) 0.81
Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials. Diagn Microbiol Infect Dis (1996) 0.80
In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group. Diagn Microbiol Infect Dis (1998) 0.80
In-vitro activity of FK-037, a new parenteral cephalosporin. J Antimicrob Chemother (1994) 0.80
Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres. Drugs (1995) 0.79
Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone. Diagn Microbiol Infect Dis (1999) 0.79
Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems. Diagn Microbiol Infect Dis (1991) 0.78
Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates. Diagn Microbiol Infect Dis (1999) 0.78
Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group. Diagn Microbiol Infect Dis (1994) 0.78
Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group. Diagn Microbiol Infect Dis (1992) 0.78
Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials. Diagn Microbiol Infect Dis (1993) 0.78
In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds. Diagn Microbiol Infect Dis (1991) 0.78
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents Chemother (1992) 0.78
Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium. Diagn Microbiol Infect Dis (1992) 0.77
Bactericidal activity of cefotaxime, desacetylcefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis (1995) 0.77
Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas. Int J Antimicrob Agents (2000) 0.77
In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates. Antimicrob Agents Chemother (1991) 0.76
Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States. Diagn Microbiol Infect Dis (1997) 0.76
New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria. Diagn Microbiol Infect Dis (1992) 0.75
Ceftizoxime interpretive criteria for in vitro susceptibility tests with Neisseria gonorrhoeae. J Clin Microbiol (1993) 0.75
Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporin. J Clin Microbiol (1992) 0.75
Disk diffusion susceptibility test interpretive criteria for GR69153, a new catechol-substituted cephalosporin. J Clin Microbiol (1991) 0.75
Evaluation of the Etest for determinations of antimicrobial spectrum and potency against anaerobes associated with bacterial vaginosis and peritonitis. Clin Infect Dis (1995) 0.75
Preliminary interpretive susceptibility testing criteria for FK-037 with 30-microgram disks. J Clin Microbiol (1994) 0.75
Determination of MIC quality control ranges for ABT-733, a novel ketolide antimicrobial agent. Quality Control Study Group. J Clin Microbiol (2000) 0.75
Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group. Diagn Microbiol Infect Dis (1991) 0.75
Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates. Eur J Clin Microbiol Infect Dis (1991) 0.75
Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella. Diagn Microbiol Infect Dis (1992) 0.75
False resistance to metronidazole by E-test among anaerobic bacteria investigations of contributing test conditions and medium quality. Diagn Microbiol Infect Dis (1996) 0.75
In vitro antimicrobial activity of CP-99433 compared with other fluoroquinolones. Diagn Microbiol Infect Dis (1993) 0.75
Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis (1996) 0.75
In vitro activity of RU29246. The metabolite of a new HR916 cephalosporin ester. Diagn Microbiol Infect Dis (1992) 0.75
Roxithromycin in-vitro susceptibility testing of Haemophilus influenzae by NCCLS methods. National Committee for Clinical Laboratory Standards. J Antimicrob Chemother (1993) 0.75
Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks. Diagn Microbiol Infect Dis (1994) 0.75
Antimicrobial activity of 11 newer and investigational drugs tested against aerobic isolates from spontaneous bacterial peritonitis. Diagn Microbiol Infect Dis (1995) 0.75
Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods. J Antimicrob Chemother (2000) 0.75
Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group. Diagn Microbiol Infect Dis (2000) 0.75
Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group. Diagn Microbiol Infect Dis (1994) 0.75
Interpretive criteria for cefodizime in vitro susceptibility tests with Neisseria gonorrhoeae. Diagn Microbiol Infect Dis (1993) 0.75
Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin. Diagn Microbiol Infect Dis (1993) 0.75
In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 6.5%) application. Diagn Microbiol Infect Dis (1993) 0.75
Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae. Diagn Microbiol Infect Dis (1992) 0.75